Xvivo Perfusion AB (publ) (XVIPY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Xvivo Perfusion AB (publ) (XVIPY) Healthcare & Pipeline Overview

Xvivo Perfusion AB (publ) is a medical technology firm based in Gothenburg, Sweden, focused on developing advanced solutions for organ, tissue, and cell preservation and perfusion in transplantation. The company's specialized products, including the XVIVO System and STEEN Solution, support critical procedures across global markets, addressing the complex needs of transplant medicine.

What Is the Investment Thesis for XVIPY?

Xvivo Perfusion AB (publ) operates in the critical and growing medical technology sector, focusing on organ preservation and perfusion for transplantation. The company's specialized product portfolio, including the XVIVO System and STEEN Solution, addresses a vital need in improving donor organ viability and expanding the donor pool, which are significant value drivers. With a gross margin of 65.2%, the company demonstrates strong product profitability, indicating efficient cost management relative to its revenue. While its P/E ratio stands at 115.06, reflecting a premium valuation, this often suggests investor confidence in future growth prospects within innovative healthcare segments. The company's global reach across North America, Europe, and Asia Pacific provides a broad market for expansion as transplantation rates potentially increase worldwide. However, investors should note the company's Beta of 1.42, indicating higher volatility compared to the broader market. Key growth catalysts include the increasing adoption of advanced perfusion techniques like EVLP, potential expansion into new organ preservation markets, and regulatory approvals for new or enhanced products. Risks encompass intense competition, regulatory hurdles inherent in medical devices, and the specialized nature of its market.

Based on FMP financials and quantitative analysis

XVIPY Key Highlights

• Market Capitalization stands at $0.21 billion, reflecting the company's current valuation in the medical technology sector.
• A P/E ratio of 115.06 suggests a premium valuation, indicating investor expectations for future earnings growth in its specialized market.
• The company maintains a strong Gross Margin of 65.2%, demonstrating efficient cost management and robust profitability on its core products.
• A Profit Margin of 8.9% indicates the company's ability to convert revenue into net income after all expenses.
• With a Beta of 1.42, XVIPY exhibits higher volatility relative to the overall market, which may appeal to investors seeking higher risk-adjusted returns.

Who Are XVIPY's Competitors?

XVIPY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XVIPY's Key Strengths?

• Specialized and comprehensive product portfolio for organ preservation and perfusion.
• Strong gross margin of 65.2% indicates efficient production and pricing power.
• Global market presence across multiple continents, diversifying revenue streams.
• Focus on innovative technologies like EVLP, addressing a critical need in transplantation.

What Are XVIPY's Weaknesses?

• High P/E ratio of 115.06 suggests premium valuation, potentially limiting upside if growth slows.
• Relatively small market capitalization of $225M compared to larger medical device companies.
• High Beta of 1.42 indicates stock price volatility, which may deter risk-averse investors.
• Reliance on the highly specialized and regulated organ transplantation market.

What Could Drive XVIPY Stock Higher?

• Increased adoption of ex vivo lung perfusion (EVLP) technology by transplant centers globally, driving demand for the XVIVO System and STEEN Solution.
• Expansion of the company's product portfolio to include preservation and perfusion solutions for other organ types beyond lungs, broadening its addressable market.
• Favorable outcomes from ongoing clinical studies or regulatory approvals for new or enhanced products, validating their efficacy and safety.
• Strategic partnerships or distribution agreements in new geographic markets, extending the company's reach and sales channels.
• General growth in global organ transplantation rates, leading to higher demand for specialized preservation and perfusion technologies.

What Are the Key Risks for XVIPY?

• Intense competition from larger, more diversified medical device manufacturers with greater resources for R&D and market penetration.
• Stringent and evolving regulatory requirements in the medical device sector, which could lead to delays in product development or market approval.
• Fluctuations in currency exchange rates between the Swedish Krona and the U.S. Dollar, impacting the value of the ADR for U.S. investors.
• Dependence on the availability of donor organs and the overall success rates of transplantation procedures, which can influence market demand.
• Risks associated with trading on the OTC 'Other' tier, including lower liquidity, limited disclosure, and potential price volatility.

What Are the Growth Opportunities for XVIPY?

• **Expansion of Ex Vivo Lung Perfusion (EVLP) Adoption:** The increasing global acceptance and utilization of EVLP technology present a significant growth opportunity. As more transplant centers adopt EVLP to assess and recondition marginal donor lungs, Xvivo Perfusion's XVIVO System (XPS) and STEEN Solution are positioned to benefit directly. This technology allows for the use of lungs that would otherwise be rejected, thereby expanding the donor pool and increasing the number of successful lung transplants. The market for EVLP is still developing, with significant potential for growth as clinical evidence continues to support its efficacy and safety, driving demand for Xvivo's integrated solutions over the next 5-10 years.
• **Geographic Market Penetration:** While Xvivo Perfusion already operates across multiple continents, there remains substantial opportunity for deeper penetration into existing markets and expansion into new emerging economies. Many regions still face significant challenges in organ transplantation due to infrastructure limitations or less advanced medical practices. By strategically expanding its sales and distribution networks, and potentially establishing local partnerships, Xvivo Perfusion can tap into underserved markets. This geographic expansion could lead to increased sales volumes and market share, particularly in regions with growing healthcare expenditures and increasing awareness of advanced transplant techniques over the medium to long term.
• **Development of Solutions for Other Organs:** Currently, Xvivo Perfusion's primary focus appears to be on lung preservation and perfusion. Expanding its research and development efforts to create similar advanced solutions for other organs, such as kidneys, livers, or hearts, represents a substantial growth avenue. The principles of ex vivo perfusion and specialized preservation solutions are applicable across various organ types. Successfully developing and commercializing products for multi-organ transplantation would significantly broaden the company's addressable market and diversify its revenue streams. This strategic expansion would likely involve a multi-year R&D and regulatory approval timeline, but offers substantial long-term growth potential.
• **Technological Advancements and Product Innovation:** Continuous innovation in organ preservation and perfusion technologies is crucial for maintaining a competitive edge and driving growth. Xvivo Perfusion has the opportunity to invest further in R&D to enhance its existing products, improve perfusion efficacy, extend preservation times, or integrate AI/machine learning for better organ assessment. Developing next-generation devices or solutions that offer superior outcomes or greater ease of use could solidify its market leadership. Such advancements could also lead to new intellectual property, strengthening its competitive moat and attracting new customers seeking state-of-the-art transplant technologies within a 3-7 year horizon.
• **Increased Transplantation Rates and Donor Pool Expansion:** Global efforts to increase organ donation rates and expand the criteria for acceptable donor organs directly benefit companies like Xvivo Perfusion. As medical advancements and public awareness campaigns lead to more available organs, the demand for sophisticated preservation and perfusion technologies will naturally rise. Xvivo's solutions, particularly those that enable the use of marginal organs, are critical enablers in this trend. The long-term growth of the organ transplantation market, driven by demographic shifts and medical progress, provides a foundational tailwind for Xvivo Perfusion's business model, ensuring sustained demand for its specialized products over the coming decades.

What Opportunities Does XVIPY Have?

• Increasing global demand for organ transplantation and expanding donor pools.
• Potential for product line expansion into preservation solutions for other organs (e.g., heart, kidney).
• Deeper penetration into existing geographic markets and entry into new emerging economies.
• Technological advancements in perfusion and preservation methods driving demand for innovative solutions.

What Threats Does XVIPY Face?

• Intense competition from larger, more diversified medical device companies.
• Stringent and evolving regulatory landscape for medical devices, potentially delaying product approvals.
• Dependence on the availability of donor organs and the success rates of transplant procedures.
• Economic downturns or healthcare policy changes impacting hospital budgets and procurement.

What Are XVIPY's Competitive Advantages?

• Specialized product portfolio focused on organ preservation and perfusion, creating a niche market expertise.
• Proprietary solutions like STEEN Solution and the integrated XVIVO System, which are critical components in advanced EVLP procedures.
• Regulatory approvals and clinical validation for its medical devices, establishing credibility and market access.
• Global distribution network and established presence in key transplant markets, providing a broad reach.

What Does XVIPY Do?

Xvivo Perfusion AB (publ) is a pioneering medical technology company, incorporated in 1998 and headquartered in Gothenburg, Sweden. The company has evolved to become a key developer of specialized solutions for organ, tissue, and cell preservation and perfusion, critical processes in the field of transplantation. Its comprehensive product portfolio is designed to enhance the viability and safety of donor organs, thereby improving transplant outcomes. Xvivo Perfusion's offerings are utilized in various global regions, including Sweden, the United States, broader North and South America, Europe, the Middle East, Africa, and the Asia Pacific, underscoring its international market presence. Central to its product line is the XVIVO System (XPS), an integrated, off-the-shelf cardiac bypass system engineered to facilitate normothermic ex vivo lung perfusion (EVLP). This system includes all necessary components for safely conducting EVLP, a procedure that allows for the assessment and reconditioning of donor lungs outside the body before transplantation. Complementing the XPS is the XPS Disposable Lung Kit, which provides sterile disposables and pre-packed products essential for the EVLP process. Another flagship product is STEEN Solution, a buffered extracellular solution specifically formulated for perfusing isolated donor lungs during EVLP, optimizing their condition for transplant. Beyond lung-specific solutions, Xvivo Perfusion also offers Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution used for general organ preservation. The company's product range further extends to specialized accessories such as the XVIVO Silicone Tubing Set for rapid flushing of donor lungs, and the XVIVO LS and XVIVO Disposable Lung Set, which are devices for EVLP. Additionally, Xvivo Perfusion provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporary storage of isolated lungs, and the XVIVO Lung Cannula Set, another single-use sterile disposable product. Through these innovations, Xvivo Perfusion AB (publ) positions itself at the forefront of advancing transplantation medicine globally.

What Products and Services Does XVIPY Offer?

• Develops solutions for organ, tissue, and cell preservation and perfusion in transplantation.
• Offers the XVIVO System (XPS), an integrated cardiac bypass system for ex vivo lung perfusion (EVLP).
• Provides the XPS Disposable Lung Kit, containing sterile disposables for EVLP procedures.
• Manufactures STEEN Solution, a buffered extracellular solution for perfusing isolated donor lungs.
• Supplies Perfadex Plus, an extracellular preservation solution for general organ preservation.
• Produces specialized accessories like XVIVO Silicone Tubing Sets and XVIVO Organ Chambers for transplant procedures.
• Operates globally, serving markets across North America, South America, Europe, the Middle East, Africa, and Asia Pacific.
• Focuses on improving the viability and safety of donor organs to enhance transplant outcomes.

How Does XVIPY Make Money?

• Sells integrated medical device systems, such as the XVIVO System (XPS), to hospitals and transplant centers.
• Generates recurring revenue from the sale of disposable kits and specialized solutions, like the XPS Disposable Lung Kit and STEEN Solution, which are consumed with each procedure.
• Provides preservation solutions, such as Perfadex Plus, used for various organ types during transplantation.
• Distributes its products through direct sales forces and potentially through partnerships in various international markets.

What Industry Does XVIPY Operate In?

Xvivo Perfusion AB (publ) operates within the Medical Devices industry, a segment of the broader Healthcare sector characterized by continuous innovation and stringent regulatory oversight. The company specifically targets the organ transplantation market, which is driven by an increasing global demand for viable organs due to rising incidences of organ failure. Key market trends include the adoption of advanced organ preservation techniques, such as ex vivo perfusion, which aims to expand the donor pool and improve post-transplant outcomes. Xvivo Perfusion's focus on integrated systems like the XVIVO System and specialized solutions like STEEN Solution positions it as a niche player providing critical technologies for these evolving practices. The competitive landscape in medical devices for transplantation involves both established large-cap medical device companies and smaller, specialized firms. Xvivo Perfusion differentiates itself through its dedicated focus on perfusion and preservation solutions, aiming to capture market share by offering clinically proven and comprehensive systems that address specific challenges in organ transplantation.

Who Are XVIPY's Key Customers?

• Transplant centers and hospitals performing organ transplantation procedures.
• Surgeons and medical professionals specializing in cardiothoracic and general surgery.
• Organ procurement organizations (OPOs) involved in donor organ retrieval and preparation.
• Research institutions and academic medical centers focused on transplant medicine advancements.

Company Profile

Xvivo Perfusion AB (publ) operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Gothenburg, SE. The company is led by CEO Christoffer Rosenblad. XVIPY has traded publicly since 2022.

F-Score 5/9Financial Health

Xvivo Perfusion AB (publ)'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.32 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE 4%Key Financial Metrics

Return on equity for Xvivo Perfusion AB (publ) stands at 4.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.5%, showing how much profit it generates from its asset base. XVIPY trades at a trailing price-to-earnings ratio of 83.79, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.2%, the inverse of the P/E and a quick read on earnings relative to price.

XVIPY Valuation & Market Position

With a $225M market cap, Xvivo Perfusion AB (publ) sits in the micro-cap segment of the market. Relative to its peer group, XVIPY's quantitative score of 60/100 is below the peer average of 70/100.

FY2026 estForward Outlook

Wall Street analysts project Xvivo Perfusion AB (publ) revenue of about $1.00B for fiscal 2026, with EPS near $0.00. The estimate reflects 4 contributing analysts.

XVIPY Financials

XVIPY Latest News

No recent news available for XVIPY.

XVIPY Analyst Consensus

XVIPY MoonshotScore

Common Questions About XVIPY (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources